Communiqués de presse
Archives
VBI Announces Acquisition of Epixis and its Innovative eVLP Vaccine Platform Companies Builde
2011/09/15
CAMBRIDGE, Mass.—(BUSINESS WIRE)—VBI Vaccines (VBI), a biotechnology company dedicated to the innovative formulation, development and delivery of safe and effective vaccines, announced today that it has completed the acquisition of Epixis S.A., a French biotechnology company developing its “eVLP” platform technology for a new generation of Virus-Like Particle (VLP) vaccines. The acquisition is complementary to VBI’s suite of thermostable vaccine formulation technologies and enables VBI to develop its own VLPbased vaccines.
In order to receive
Genopole® press releases®,
please provide your coordinates
to Press Service
